Type I interferons and the quality of life of multiple sclerosis patients. Results from a clinical trial on interferon alfa-2a

Abstract

The objective of the study was to examine whether the beneficial effect of treatment of interferon alfa-2a on multiple sclerosis seen by magnetic resonance imaging is reflected in a corresponding improvement in the quality of life (QoL) and to address the impact of adverse events related to this treatment on the QoL. The study was a randomised double-blinded placebo-controlled treatment trial including 97 relapsing-remitting multiple sclerosis patients. Thirty-two patients received 4.5 MIU recombinant interferon alfa-2a, 32 patients received 9.0 MIU recombinant interferon alfa- 2a and 33 patients received placebo treatment for 6 months. All patients were followed up 6 months after end of treatment. QoL was assessed according to the eight scales of the SF-36 Health Survey and measured at baseline, month 3, 6 and 12. The effect found on MRI was not reflected in a corresponding change in the QoL. We found a relationship between the presence of new enhancing lesions and reduced QoL among the placebo patients, whereas this was not found among the patients treated with interferon. The presence of the adverse events fatigue, myalgia, headache and weakness were significantly negatively correlated to several of the QoL dimensions. Conclusively, the treatment with interferon alfa- 2a does not seem to improve the patients' QoL after 6 months of treatment, in spite of a marked effect measured by MRI. The treatment is followed by adverse events that negatively affected the QoL.

Keywords

multiple sclerosis quality of life SF-36 Health Survey clinical trial type I interferons

Get full access to this article

View all access options for this article.

References

The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group . (1995) Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial . Neurology 45: 1277-1285 .

Jacobs LD et al. (1996) Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG) . Ann Neurol 39: 285-294 .

Durelli L et al. (1994) Chronic systemic high-dose recombinant interferon alfa-2a reduces exacerbation rate, MRI signs of disease activity, and lymphocyte interferon gamma production in relapsing-remitting multiple sclerosis . Neurology 44: 406-413 .

Pozzilli C et al. (1996) Magnetic resonance imaging changes with recombinant human interferon-beta-1a: a short term study in relapsing-remitting multiple sclerosis . J Neurol Neurosurg Psychiatry 61: 251-258 .

McKee L. (1998) Interferon beta produces only small benefits in multiple sclerosis (news) . BMJ 316: 1410-1410 .

Quality and life and clinical trials . (1995) Editorial. Lancet 346: 1-2 .

Rothwell PM , McDowell Z , Wong CK , Dorman PJ. (1997) Doctors and patients don't agree: cross sectional study of patients' and doctors' perceptions and assessments of disability in multiple sclerosis . BMJ 314: 1580-1583 .

Andersson PB , Waubant E , Goodkin DE. (1997) How should we proceed with disease-modifying treatments for multiple sclerosis? Lancet 349: 586-587 .

LaRocca NG et al. (1996) `Quality of Life' Assessment in Multiple Sclerosis Clinical Trials: Current Status and Strategies for Improving Multiple Sclerosis Clinical Trial Design. In: Goodkin DE , Rudick RA (eds). Multiple Sclerosis, Advances in Clinical Trial Design, Treatment and Future Perspectives. Springer: London . pp 145-160.

10.

Rudick RA , Sibley W , Durelli L. (1996) Treatment of Multiple Sclerosis with Type I Interferons. In: Goodkin DE , Rudick RA (eds). Multiple Sclerosis, Advances in Clinical Trial Design, Treatment and Future Perspectives. Springer: London pp 223-250.

11.

Myhr KM et al. (1999) Interferon alfa-2a reduces MRI disease activity in relapsing-remitting multiple sclerosis . Neurology, 52: 1049-1056 .

12.

Nyland et al. (1996) Treatment of relapsing-remittent multiple sclerosis with recombinant human interferon-alfa-2a: design of a randomised, placebo-controlled, double blind trial in Norway . Multiple Sclerosis 1: 372-375 .

13.

Poser CM et al. (1983) New diagnostic criteria for multiple sclerosis: guidelines for research protocols . Ann Neurol 13: 227-231 .

14.

Kurtzke JF. (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS) . Neurology 33: 1444-1452 .

15.

WHO handbook for reporting results of cancer treatment. (1979) Geneva: World Health Organization , WHO Offset Publications, No. 48.

16.

Radosevich DM , Wetzler H , Wilson SM. (1994) Health Status Questionnaire 2.0: scoring comparisons and reference data. Bloomington, MN: Health Outcome Institute .

17.

Loge JH , Kaasa S. (1998) Short form 36 (SF-36) health survey: normative data from the general Norwegian population . Scand J Soc Med, 26: 250-258 .

18.

Ware JE. SF-36 Health Survey manual & interpretation guide. (1993) Nimrod Press: Boston .

19.

Brazier JE et al. (1992) Validating the SF-36 Health Survey questionnaire: new outcome measure for primary care . BMJ 305: 160-164 .

20.

Loge JH , Kaasa S , Hjermstad MJ , Kvien TK. (1998) Translation and performance of the Norwegian SF-36 Health Survey in patients with rheumatoid arthritis. I: Data Quality, Scaling assumptions, reliability and construct validity . J Clin Epidemiol 51: 1069-1076 .

21.

The Canadian Burden of Illness Study Group . (1998) Burden of illness of multiple sclerosis. Part II: Quality of Life . Can J Neurol Sci 25: 31-38 .

22.

Schwartz CE , Coulthard-Morris L , Cole B , Vollmer T. (1997) The quality-of-life effects of interferon beta-1b in multiple sclerosis. An extended Q-TWiST analysis . Arch Neurol 54: 1475-1480 .

23.

Miller DH. (1997) Has magnetic resonance imaging become a surrogate marker in multiple sclerosis? In: Thompson AJ , Polman C , Hohlfeld R , (eds). Multiple Sclerosis: clinical challenges and controversies. Martin Dunitz Ltd: London pp 195-210.